Edition 7: TAVR, IV vs IO, ERCP risk plateaus, dementia and cannabis.

From FIT screening outpacing colonoscopy in participation to anti-CD20 drugs showing lasting MS control at 7+ years, this edition brings clarity to complex clinical choices. We examine how metabolic syndrome increases young-onset dementia risk by 24%, why post-ERCP pancreatitis rates haven’t budged in two decades, and the unchanged survival edge between IO and IV access in cardiac arrest.

As phthalates in plastics are linked to 350,000 heart deaths and cannabis use raises dementia odds, we separate correlation from causation. Meanwhile, fecal therapy via colonoscopy proves safe and 95% effective for recurrent C. diff, and FDA expands TAVR for asymptomatic aortic stenosis with a 50% lower risk of death, stroke, or hospitalization.